Erlenmeyer Flask

Huy A. Tran

Hunter Area Pathology Service, John Hunter Hospital, New South Wales 2310, Australia

Address all correspondence and requests for reprints to: Dr. Huy A. Tran, Department of Clinical Chemistry, Hunter Area Pathology Service, John Hunter Hospital, New South Wales 2310, Australia. E-mail: huy.tran{at}hunter.health.nsw.gov.au.

A 28-yr-old female with long-standing Gaucher’s disease (type I) presented with acute onset of lower leg pain. Physical examination revealed generalized tenderness in the proximal left tibia with mild pyrexia of 37.8 C. Further investigations included magnetic resonance imaging (MRI), which showed significant fatty bone marrow infiltrate in both femurs and tibias (Figs. 1AGo and 2Go). Both, but more so in the femurs, displayed the typical "Erlenmeyer flask" appearance (Fig. 1BGo).



View larger version (93K):
[in this window]
[in a new window]
 
FIG. 1. A classical Erlenmeyer deformity. A, T2-weighted MRI image of both femurs giving the typical appearance of Erlenmeyer flask deformity (arrows). Note the diffuse bone marrow infiltration and intact femoral heads, ruling out osteonecrosis as a possible cause of pain. B, An Erlenmeyer flask. These inverted conical flasks were invented in 1861 by the German chemist Emil Richard August Carl Erlenmeyer (1825–1909) and have been used ubiquitously in laboratories throughout the world. Dr. Erlenmeyer was the first chemist to synthesize tyrosine, guanidine, creatine, and creatinine (3 ). In 1880, the Erlenmeyer rule indicated that all alcohols in which the hydroxyl group was attached directly to a double-bonded carbon atom became aldehydes or ketones.

 


View larger version (136K):
[in this window]
[in a new window]
 
FIG. 2. T2-weighted MRI image of the tibias demonstrating extensive and diffuse marrow infiltration. Note a focus of decreased T2-weighted signals with a heterogenous pattern, surrounded by a low signal rim in the left femur (arrow). This is suggestive of marrow infarct as the cause of pain.

 
The deformity was due to the impairment of remodeling in the metaphyseal region of long bones but was not pathognomonic of this condition (1). Other bony features in Gaucher’s disease included osteopenia (particularly in children), osteoclerosis, and, less commonly, osteonecrosis. The latter was excluded clinically because of the negative MRI appearance. The patient’s pain was thought to be due to bone marrow infarct (arrow, Fig. 2Go), and the mechanism was thought to occur secondarily to infiltration with Gaucher’s cells. The condition generally resolved with analgesia and conservative therapy (2).


    Footnotes
 
Abbreviation: MRI, Magnetic resonance imaging.

Received June 29, 2004.

Accepted July 2, 2004.


    References
 Top
 References
 

  1. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B 2002 Skeletal aspects of Gaucher disease: a review. Br J Radiol 75(Suppl 1):A2–A12
  2. Beutler E, Grabowski GA 2001 Gaucher’s disease. In: Scriver RC, Beaudet AL, Sly WS, Valle D, eds. The metabolic, molecular bases of inherited disease. Chap 146. Vol III. 8th ed. New York: McGraw-Hill Companies; 3635–3656
  3. Erlenmeyer, Richard A. C. E. 2001 The Columbia encyclopedia. 6th ed. New York: Columbia University Press




This Article
Full Text (PDF)
Submit a related Letter to the Editor
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me when eLetters are posted
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Request Copyright Permission
Google Scholar
Articles by Tran, H. A.
Articles citing this Article
PubMed
PubMed Citation
Articles by Tran, H. A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals